|
Vaccine Therapy and Detection of Immunologic Responses with Human Papillomavirus 16 E6 and E7 Peptides in Patients with Metastatic or Locally Advanced Cervical Cancer and Other Cancers Carrying the HPV Clinical Trials Info presented on Clinical Trials Search isn't intended to be a substitute for certified health advice, travels to or treatment by using a genuine physician. We are not physicians. Always consult your dr. on Vaccine Therapy and Detection of Immunologic Responses with Human Papillomavirus 16 E6 and E7 Peptides in Patients with Metastatic or Locally Advanced Cervical Cancer and Other Cancers Carrying the HPV conditions. Clinical Trials Search.org is a site committed to listing clinical research studies in human subjects. Vaccine Therapy and Detection of Immunologic Responses with Human Papillomavirus 16 E6 and E7 Peptides in Patients with Metastatic or Locally Advanced Cervical Cancer and Other Cancers Carrying the HPV Clinical research trials and Vaccine Therapy and Detection of Immunologic Responses with Human Papillomavirus 16 E6 and E7 Peptides in Patients with Metastatic or Locally Advanced Cervical Cancer and Other Cancers Carrying the HPV health trials occur in hundreds of cities throughout the U.S.A.. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials typically assess the effectivity of new drugs. The propose of the studies / undertakings is to resolve certain human health questions. Clinical trials are a popular means for physicians, government agencies, and private sector companies to locate treatments for all sorts of conditions, including Vaccine Therapy and Detection of Immunologic Responses with Human Papillomavirus 16 E6 and E7 Peptides in Patients with Metastatic or Locally Advanced Cervical Cancer and Other Cancers Carrying the HPV. Vaccine Therapy and Detection of Immunologic Responses with Human Papillomavirus 16 E6 and E7 Peptides in Patients with Metastatic or Locally Advanced Cervical Cancer and Other Cancers Carrying the HPV Clinical Trials and other clinical trials permit volunteers to acquire medical treatment choices before they are available to the masses. Some times the test subjects obtain professional assistance for free, and every now and again they are compensated for their time. Sometimes there is a cost for a Vaccine Therapy and Detection of Immunologic Responses with Human Papillomavirus 16 E6 and E7 Peptides in Patients with Metastatic or Locally Advanced Cervical Cancer and Other Cancers Carrying the HPV clinical trial. Participants oftentimes recieve the most expert healthcare available for their Vaccine Therapy and Detection of Immunologic Responses with Human Papillomavirus 16 E6 and E7 Peptides in Patients with Metastatic or Locally Advanced Cervical Cancer and Other Cancers Carrying the HPV condition. Hazards are a reality, however, and can include extra or frequent physician visits, health risks (potentially life-endangering), and/or the treatment being uneffective. Trials are federally governed with rigorous guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "V" Clinical Trials Conditions > Vaccine Therapy and Detection of Immunologic Responses with Human Papillomavirus 16 E6 and E7 Peptides in Patients with Metastatic or Locally Advanced Cervical Cancer and Other Cancers Carrying the HPV  Vaccine Therapy and Detection of Immunologic Responses with Human Papillomavirus 16 E6 and E7 Peptides in Patients with Metastatic or Locally Advanced Cervical Cancer and Other Cancers Carrying the HPV
Vaccine Therapy and Detection of Immunologic Responses with Human Papillomavirus 16 E6 and E7 Peptides in Patients with Metastatic or Locally Advanced Cervical Cancer and Other Cancers Carrying the HPV
For Condition: Anus Neoplasm,Cervix Neoplasm,Esophageal Neoplasm,Head and Neck Neoplasm,Papovaviridae Infection
Status: No longer recruiting
Sponsor(s): National Cancer Institute (NCI) ,
Synopsis: Group A: Patients have cervical cancer stage IV, recurrent disease, or stage III disease that did not receive appropriate radiation therapy, and patients with other advanced tumors which harbor HPV such as anogenital, esophageal or head and neck cancers. A total of 12 patients will be accrued, 6 patients receive vaccination with HPV16 E6 and the other 6 receive HPV16 E7 peptides. Group B: Patients have stage III cervical carcinomas that have been treated with standard therapy with no evidence of residual disease. Vaccination in this group is given as an adjuvant therapy. A total of 12 patients will be accrued, 6 patients receive vaccination with HPV16 E6 and the other 6 receive HPV16 E7 peptides. Patients in Group A and Group B are assigned to either E6 or E7 by the Principal Investigator. The following acronyms are used: APC Antigen-Presenting Cells HPV16 Human Papillomavirus 16 PBMC Peripheral Blood Mononuclear Cells Vaccine Therapy. Vaccination with autologous APC (PBMC pulsed in vitro with HPV16 E6 or E7 peptide).
Details: HPV genes and their protein products have been identified in most cervical as well as other anogenital carcinomas. More than 90% of human cervical carcinomas harbor high risk HPV DNA most of which are HPV 16 and 18. The product of the early genes E6 and E7 open reading frames of these viruses have been implicated in the transformation of cervical cancer and are considered the oncogenic products of the HPV DNA genome. Endogenous proteins in the cell, whether of self (e.g. oncoproteins) or foreign (e.g. viral proteins) origin, are degraded in the cells. Fragments of these degraded proteins are presented as small peptides bound to the major histocompatibility complex (MHC) class I molecules on the surface of the cells. These peptides are potentially immunogenic for T lymphocytes. It has been shown that immunizing mice with nontumorigenic APC's transfected with the HPV16-E7 gene conferred protection against transplanted syngeneic tumor cells expressing HPV16-E7. This protection was mediated by CD8+ lymphocytes. Regression of transplanted tumor expressing HPV16-E6 has also been demonstrated after immunizing mice with syngeneic fibroblast expressing HPV16-E6 protein, and this immunologic response was also shown to be mediated through CTLs. Also, HPV16-E7 peptide was shown to bind with high affinity to the mouse H-2D(b) MHC I molecule. After vaccination, mice were rendered insensitive to subsequent challenge with HPV16-transformed tumor cells. Thus, HPV E6 and E7 proteins can serve as tumor antigens for CTLs which can lyse tumor cells. These CTLs can be generated in vivo by vaccination of mice with synthetic peptides that are able to bind MHC class I molecules. Therefore, in the present study we propose to test whether HPV E6 and E7 proteins are processed and presented in human tumors for T cell recognition, and if they can therefore be targets for specific peptide vaccination.
Eligibility:
Study Type: Interventional, Treatment, Safety
Minimum Age/Maximum Age: /
Genders: Female
Protocol Entry Criteria: INCLUSION CRITERIA: Histologic diagnosis of squamous cell carcinoma of the cervix. The patient should have stage III, IV, or recurrent disease. Tumor tissue availability for the determination of the presence of the HPV genome and its type (paraffin block, or fresh tissue). The tumors should harbor the genome of HPV16. The patient should be HLA-A2.1 subtype. It is preferable to have tumor tissue available for preparation of a tumor cell line, and tumor or lymph node tissue for expansion of tumor infiltrating lymphocytes (TIL) for in vitro immunologic laboratory studies. If fresh tissue is not available the patient may be requested to undergo a biopsy procedure if his/her medical status allows the procedure to be performed with minimal risk. The patient should not have received chemotherapy, radiation therapy, immunotherapy, or steroids for at least 4 weeks prior to starting vaccination. The patient should have recovered from all acute toxicities of previous treatment. Patients should be more than 18 years old. ECOG performance status of 0 or 1. The patient should be able to give an informed consent. Life expectancy greater than 3 months. While measurable disease is preferable, in stage IV and recurrent disease, it is not a necessity. All patients must have a signed informed consent, registered through Orkand before entering on the study. An adequate T cell response to an HLA-A2 Flu peptide. We define adequate response as either 2 fold increase of IFN gamma response over control (unpulsed target cells), or and increase of 10 % specific lysis over control. EXCLUSION CRITERIA: Any condition inconsistent with the inclusion criteria. HIV infection. Pregnancy or nursing. Patient with reproductive potential must have a negative pregnancy test. Patient of reproductive age should use adequate contraception. Any of the following: WBC less than 2000. Lymphocytes less than 800, Platelets less than 100K; Creatinine greater than 2.0 mg/dl; Serum Bilirubin greater than 2.0 mg/dl, SGPT greater than 4 times normal. Active second malignancy other than basal cell carcinoma of the skin. History of CNS metastasis. Active ischemic heart disease (i.e. Class III or VI cardiac disease-New York Heart Association), or a recent history of myocardial infarction (within the last 6 months). Unresponsiveness to skin test antigens including all the following PPD, Mumps Tricophyton, Candida and Tetanus. Autoimmune disease e.g., SLE, MS, ankylosing spondylitis, etc. Active infection requiring antibiotics. Patients requiring steroids. Weight loss of greater than 20% of prediagnosis body weight.
Total Enrollment: 46
Location and Contact Information:
National Cancer Institute (NCI)
Bethesda, Maryland, 20892
United States
Additional Information:
Study ID Numbers: 950154; 95-C-0154
Study Start Date: July 5, 1995
Record last reviewed: May 5, 2003
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00001441
Other Papovaviridae Infection Studies:
1. Vaccine Therapy and Detection of Immunologic Responses with Human Papillomavirus 16 E6 and E7 Peptides in Patients with Metastatic or Locally Advanced Cervical Cancer and Other Cancers Carrying the HPV
Related Studies:
Other Papovaviridae Infection Clinical Trials
Other Maryland Clinical Trials
Other Bethesda Clinical Trials
Vaccine Therapy and Detection of Immunologic Responses with Human Papillomavirus 16 E6 and E7 Peptides in Patients with Metastatic or Locally Advanced Cervical Cancer and Other Cancers Carrying the HPV
|
|
|
|
|
|
|
|
